Fertility and Sterility
Volume 88, Issue 4 , Pages 781-784, October 2007

Substandard application of preimplantation genetic screening may interfere with its clinical success

  • Santiago Munné, Ph.D.

      Affiliations

    • Reprogenetics, Livingston, New Jersey
    • Corresponding Author InformationReprint requests: Santiago Munné, Ph.D., Reprogenetics, 3 Regent Street, Suite 301, Livingston, New Jersey 07039 (FAX: 973-992-1423).
    • ,
  • Luca Gianaroli, M.D.

      Affiliations

    • S.I.S.Me.R., Bologna, Italy
    • ,
  • Ilan Tur-Kaspa, M.D.

      Affiliations

    • Reproductive Genetics Institute, Chicago, Illinois
    • ,
  • Cristina Magli, Ph.D.

      Affiliations

    • S.I.S.Me.R., Bologna, Italy
    • ,
  • Mireia Sandalinas, M.Sc.

      Affiliations

    • Reprogenetics-Spain, Barcelona, Spain
    • ,
  • Jamie Grifo, M.D.

      Affiliations

    • New York University, New York, New York
    • ,
  • David Cram, Ph.D.

      Affiliations

    • Monash IVF, Clayton, Victoria, Australia
    • ,
  • Semra Kahraman, M.D.

      Affiliations

    • Istanbul Memorial Hospital, Istanbul, Turkey
    • ,
  • Yury Verlinsky, Ph.D.

      Affiliations

    • Reproductive Genetics Institute, Chicago, Illinois
    • ,
  • Joe L. Simpson, M.D.

      Affiliations

    • Florida International University College of Medicine, Miami, Florida

Received 29 July 2007; received in revised form 3 August 2007; accepted 3 August 2007.

The intent of this study was to evaluate a recent randomized clinical trial evaluating the effect of preimplantation genetic screening (PGS) that reports a negative effect on pregnancy outcome. This article reviews appropriate PGS techniques and how they differ from the trial in question. A closer look at the clinical trial in question reveals significant lack of expertise in biopsy, cell fixation, genetic analysis, and patient selection. At most, this trial demonstrates that in inexperienced hands, PGS can be detrimental. No other conclusions concerning the effect of PGS on pregnancy results can be drawn from the trial.

Key Words: Preimplantation genetic diagnosis, PGD, recurrent miscarriage, recurrent pregnancy loss, aneuploidy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 S.M. is Director of Reprogenetics, a laboratory specializing in preimplantation genetic diagnosis. I.T.-K. has received research funding from Serono and is on the speaker's bureau for Organon. M.S. has a financial interest in Reprogenetics. Y.V. is owner and chief executive officer of Reproductive Genetics Institute, which operates clinics that provide preimplantation genetic diagnosis. J.L.S. is a member of the medical advisory board for Biocept and is a member of the scientific advisory board for IMETRIKUS.

PII: S0015-0282(07)03052-X

doi:10.1016/j.fertnstert.2007.08.002

Fertility and Sterility
Volume 88, Issue 4 , Pages 781-784, October 2007

Article Tools